Garassino, M.Cho, B. C.Kim, J.Mazieres, J.Vansteenkiste, J.Lena, H. H.Corral, J.Gray, J.Powderly, J.Chouaid, C.Bidoli, P.Wheatley-Price, P.Park, K.Soo, R.Huang, Y.Wadsworth, C.Dennis, P.Rizvi, N.2025-01-072025-01-072018-10-011556-0864https://hdl.handle.net/10668/27250endurvalumabprogrammed cell death ligand-1ImmunotherapySafety of Durvalumab Retreatment in Advanced NSCLC Patients Who Progressed Following Initial Disease Control In ATLANTICconference outputopen access10.1016/j.jtho.2018.08.5771556-1380http://www.jto.org/article/S1556086418315351/pdf454014501211